This Million Position Signals Conviction in Biotech Stock
When a big investor deploys tens of millions into a biotech name ahead of an FDA decision, it can signal strong convi...
Identify key moments to de-risk in retirement, using timing signals to reduce exposure while preserving income.
27,016 articlesWhen a big investor deploys tens of millions into a biotech name ahead of an FDA decision, it can signal strong convi...
Investors are buzzing as rare earth stock rocketing headlines surface. This article breaks down the drivers behind US...
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
Oklo just dropped below $50, sparking questions about long-term value. This guide breaks down what to check, how to a...
TMC trades under $7 as investors weigh the potential of seabed mining for essential metals. This guide breaks down th...
NuScale Power faced a sharp February sell-off as project delays, funding needs, and analyst downgrades weighed on the...
A federal probe into Tesla's FSD system raises questions for investors about safety, costs, and stock risk. This guid...
A leading hedge fund poured nearly $40 million into GRAIL last quarter, only to see the stock tumble. This article un...
Smart investors look beyond the loud headlines. This guide explains how overlooked stocks soar 2026 by spotting catal...
Trilogy Metals has fallen hard this week, leaving investors asking whether the downturn is a short-lived pullback or ...
Could a bold thesis around Oklo Inc. unlock life-changing gains? This forward-looking guide breaks down why nuclear e...
Nuclear energy is a long game for investors. This guide weighs NuScale Power against Oklo as a path to exposure in th...